Despite recent advances in medical and surgical treatments,surgical resection remains the only curative option for patients with colorectal liver metastasis(CRLM).Unfortunately,only a minority of patients with CRLM ar...Despite recent advances in medical and surgical treatments,surgical resection remains the only curative option for patients with colorectal liver metastasis(CRLM).Unfortunately,only a minority of patients with CRLM are candidates for liver resection.The 5-year survival of patients with liver-only disease and deemed unresectable is difficult to quantify but likely ranges around 5 to 10%.Since 2013,a few studies have shown that liver transplantation(LT)is feasible for selected patients with unresectable CRLM(1,2).Recently,the Oslo University Hospital LT group has published their latest results with modified selection criteria and should be congratulated for their efforts.Nevertheless,the evidence available is still developing.For example,currently,there is a lack of robust evidence supporting the widespread use of LT for CRLM outside Norway,a particular region in terms of graft scarcity.展开更多
There is a worldwide increase in the annual incidence of intrahepatic cholangiocarcinoma(iCCA)(1).For this reason,the review from Bupathi et al.assesses a highly relevant topic.Their work shows several important advan...There is a worldwide increase in the annual incidence of intrahepatic cholangiocarcinoma(iCCA)(1).For this reason,the review from Bupathi et al.assesses a highly relevant topic.Their work shows several important advances in the management of iCCA in the past few decades(2).They review the role of adjuvant therapy for patients with early stages and adverse prognostic factors(i.e.,lymph nodal disease).Also,they report recent achievements in the management of advanced disease.Despite the progress made in the management of iCCA,much is still to be done.展开更多
文摘Despite recent advances in medical and surgical treatments,surgical resection remains the only curative option for patients with colorectal liver metastasis(CRLM).Unfortunately,only a minority of patients with CRLM are candidates for liver resection.The 5-year survival of patients with liver-only disease and deemed unresectable is difficult to quantify but likely ranges around 5 to 10%.Since 2013,a few studies have shown that liver transplantation(LT)is feasible for selected patients with unresectable CRLM(1,2).Recently,the Oslo University Hospital LT group has published their latest results with modified selection criteria and should be congratulated for their efforts.Nevertheless,the evidence available is still developing.For example,currently,there is a lack of robust evidence supporting the widespread use of LT for CRLM outside Norway,a particular region in terms of graft scarcity.
文摘There is a worldwide increase in the annual incidence of intrahepatic cholangiocarcinoma(iCCA)(1).For this reason,the review from Bupathi et al.assesses a highly relevant topic.Their work shows several important advances in the management of iCCA in the past few decades(2).They review the role of adjuvant therapy for patients with early stages and adverse prognostic factors(i.e.,lymph nodal disease).Also,they report recent achievements in the management of advanced disease.Despite the progress made in the management of iCCA,much is still to be done.
